Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spare some colon cancer patients from chemo

NCT ID NCT06434896

Knowledge-focused Sponsor: UMC Utrecht Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a blood test that detects tiny bits of tumor DNA after surgery can help decide which stage II colon cancer patients should get chemotherapy. About 1,320 patients will be randomly assigned to either have their test results used to guide treatment or to receive standard care. The goal is to see if more patients with a positive test start chemo, and whether this approach reduces cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ctDNA blood test
What this could lead to
If successful, this could show that a simple blood test can identify which stage II colon cancer patients need chemotherapy after surgery, avoiding unnecessary treatment for others.
What could go wrong
This is an early-stage observational study, not a treatment trial. The test may not accurately predict recurrence, and the results may not change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,320 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Informed consent for PLCRC with specific consent for: * additional blood withdrawals * collection and use of tissue for scientific research * invitation for future (experimental) research within the cohort, including TwiCs studies * Inclusion in observational PLCRC -MEDOCC substudy * Histological confirmed stage II colon cancer * Fit enough to receive treatment with combination chemotherapy (fluoropyrimidine and oxaliplatin) according to the treating physician Exclusion Criteria: * Indication for adjuvant chemotherapy according to treating physician * Another malignancy in previous 5 years, with the exception of treated carcinoma in situ or skin cancer other than melanoma * Incomplete primary tumor resection (R1 or R2 resection) * Contra-indication for fluoropyrimidines or oxaliplatin * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circulating tumor DNA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm malignant colon neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Circulating tumor DNA Colon cancer stage II Recurrence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    29 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Admiraal de Ruyter Ziekenhuis

    RECRUITING

    Goes, Netherlands

  • Albert Schweizer Ziekenhuis

    RECRUITING

    Dordrecht, Netherlands

  • Amphia Ziekenhuis

    RECRUITING

    Breda, Netherlands

  • Bernhoven

    RECRUITING

    Uden, Netherlands

  • Bravis Ziekenhuis

    RECRUITING

    Roosendaal, Netherlands

  • Canisius Wilhelmina Ziekenhuis

    RECRUITING

    Nijmegen, Netherlands

  • Deventer Ziekenhuis

    RECRUITING

    Deventer, Netherlands

  • Diakonessenhuis

    RECRUITING

    Utrecht, Netherlands

  • Flevoziekenhuis

    RECRUITING

    Almere Stad, Netherlands

  • Haaglanden MC

    RECRUITING

    The Hague, Netherlands

  • Ikazia Ziekenhuis

    RECRUITING

    Rotterdam, Netherlands

  • Jeroen Bosch Ziekenhuis

    RECRUITING

    's-Hertogenbosch, Netherlands

  • Maastricht UMC

    RECRUITING

    Maastricht, Netherlands

  • Maxima Medisch Centrum

    RECRUITING

    Veldhoven, Netherlands

  • Meander Medisch Centrum

    RECRUITING

    Amersfoort, Netherlands

  • NKI-AVL

    RECRUITING

    Amsterdam, Netherlands

  • Noordwest Ziekenhuisgroep

    RECRUITING

    Alkmaar, Netherlands

  • Reinier de Graaf Gasthuis

    RECRUITING

    Delft, Netherlands

  • Rijnstate

    RECRUITING

    Arnhem, Netherlands

  • Rivas

    RECRUITING

    Gorinchem, Netherlands

  • Spaarne Gasthuis

    RECRUITING

    Haarlem, Netherlands

  • St. Antonius Ziekenhuis

    RECRUITING

    Nieuwegein, Netherlands

  • St. Jans Gasthuis

    RECRUITING

    Weert, Netherlands

  • UMC Utrecht

    RECRUITING

    Utrecht, Netherlands

  • Van Weel-Bethesda Ziekenhuis

    RECRUITING

    Middelharnis, Netherlands

  • VieCuri Medisch Centrum

    RECRUITING

    Venlo, Netherlands

  • Ziekenhuis Gelderse Vallei

    RECRUITING

    Ede, Netherlands

  • Ziekenhuis St. Jansdal

    RECRUITING

    Harderwijk, Netherlands

  • Ziekenhuisgroep Twente

    RECRUITING

    Almelo, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.